{"id":706968,"date":"2026-07-23T11:31:42","date_gmt":"2026-07-23T11:31:42","guid":{"rendered":"https:\/\/www.newsbeep.com\/uk\/706968\/"},"modified":"2026-07-23T11:31:42","modified_gmt":"2026-07-23T11:31:42","slug":"compounded-glp-1s-why-doctors-worry-and-the-fda-is-cracking-down","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/uk\/706968\/","title":{"rendered":"Compounded GLP-1s: Why doctors worry and the FDA is cracking down"},"content":{"rendered":"

So, are these copycat versions of the weight loss drugs safe? Poison control centers across the U.S. have seen a more than 15-fold increase<\/a> in calls related to injected weight loss drugs since 2019, with many of them relating to the kind of dosing errors that are easier to make with compounded drugs.<\/p>\n

We spoke with Stanford Medicine clinicians who prescribe GLP-1s daily. They say the concerns with the compounded drugs are real, but so is the cost crisis that drives people to use them.<\/p>\n

\u201cPeople ask me all the time whether these compounded drugs are an option because of the cost and access,\u201d said Michael Blyumin, PharmD, an ambulatory clinical care pharmacist at Stanford Medicine. \u201cBut I advise against it; there are a lot of potential problems that they pose.\u201d<\/p>\n

What are GLP-1 drugs and why are they so costly?<\/p>\n

GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced in the gut that tells our bodies when we\u2019ve eaten, helping regulate blood sugar and appetite. GLP-1 receptor agonists are drugs that mimic this hormone, signaling the brain to reduce hunger and make other metabolic changes. The drugs, including semaglutide (Ozempic, Wegovy and Rybelsus), tirzepatide (Mounjaro and Zepbound) and retatrutide (still in clinical trials), are used to treat both diabetes and obesity.<\/p>\n

Because they are new, patented drugs, GLP-1s can cost more than $1,000 per month at their list price. Patent laws dictate that generic versions of semaglutide won\u2019t be available in the U.S. until at least 2032, when the first main patent for the drug, held by Novo Nordisk,expires; Eli Lilly\u2019s patents on tirzepatide don\u2019t begin to expire until 2036.<\/p>\n

What makes a compounded GLP-1 \u201cunapproved\u201d?<\/p>\n

A compounded drug is made when a pharmacy \u2014 unconnected with the manufacturer of a brand-name product \u2014 formulates a custom-made version of a drug. These pharmacies serve lots of medically necessary needs, such as making a liquid version of a pill for children or a variation of a medicine for people with a severe allergy to an ingredient. However, unlike FDA-approved drugs, they don\u2019t go through the agency\u2019s review process for safety, effectiveness or quality before reaching patients.<\/p>\n

Normally, compounding a commercially available drug isn\u2019t permitted. But when GLP-1 drugs faced severe shortages beginning in 2022, the FDA allowed compounding pharmacies to begin producing it. As Blyumin put it, they \u201cwere given limited use authorizations to compound these drugs that otherwise they shouldn\u2019t be able to, because they\u2019re on patent.\u201d<\/p>\n

Now, those shortages have ended, and compounding pharmacies no longer have a legal basis for producing identical copies of GLP-1s. But eager for business, they are now formulating new variations of the drugs \u2014 adding new ingredients, using different forms of the hormones or creating new delivery methods (such as sublingual drops or tablets that dissolve under your tongue) so they can claim they are different products.<\/p>\n

<\/p>\n

\"\"\/<\/p>\n

\n Previous Next\n <\/p>\n

Addiction<\/p>\n

What are the risks of taking compounded GLP-1s?<\/p>\n

Those differences in manufacturing, ingredients and formulations are exactly what has some clinicians worried about their patients\u2019 use of compounded GLP-1s. They also worry that when patients receive drugs online from compounding pharmacies, they may not get the same level of guidance about how to take the drugs or what to expect from the compounded drug providers as they would get from a clinician.<\/p>\n

\u201cThe use of compounded drugs in patients using GLP-1s without medical supervision pose significant risk and can result in significant consequences,\u201d said Marina Basina<\/a>, MD, a clinical professor in endocrinology, gerontology and metabolism.<\/p>\n

The risks and downsides fall into several categories:<\/p>\n

Unapproved salt forms<\/p>\n

The semaglutide and tirzepatide in FDA-approved drugs have specific chemical structures that were tested extensively in clinical trials. Some compounders use chemically distinct structures known as salt forms. Rather than semaglutide, for instance, they might use semaglutide sodium, which is a version of the drug that has a sodium salt attached.<\/p>\n

These salt forms of GLP-1s have not been proven safe and effective in humans or approved by the FDA, Basina noted, adding that effectiveness \u201ccan be different due to the salt form differences.\u201d<\/p>\n

Additives<\/p>\n

To differentiate their products from the FDA-approved GLP-1s, many compounders add extra ingredients \u2014 most commonly vitamin B12, but also B6, niacinamide, glycine or carnitine \u2014 that have no proven benefit for weight loss or diabetes management.<\/p>\n

These combinations are largely untested in clinical trials. A 2026 study<\/a> found that when tirzepatide is compounded with B12, the two substances can chemically bond, forming a new molecule not found in the FDA-approved drug. The finding was replicated<\/a> by tirzepatide maker Eli Lilly, who carried out tests on the impact of mixing tirzepatide and B12 and released a statement underscoring that the clinical consequences of the new molecule are not known.<\/p>\n

Untested formulations<\/p>\n

Semaglutide and tirzepatide are FDA-approved as injectables (an oral tablet version of semaglutide is also approved), but the formulations some drug compounding pharmacies are selling in the form of sublingual drops or dissolving tablets have never been studied in clinical trials.<\/p>\n

Blyumin cautioned consumers to be wary of these formulations.<\/p>\n

\u201cNobody legitimate makes sublingual semaglutide,\u201d Blyumin said. \u201cI\u2019ve never seen data that says how efficiently it\u2019s absorbed that way.\u201d<\/p>\n

Dosing errors<\/p>\n

FDA-approved GLP-1s come in pre-filled, single-dose pens with clear instructions. Many compounded versions come in multidose vials, requiring patients to measure their own doses, a practice that introduces significant room for error. The FDA has flagged<\/a> cases in which patients inadvertently administered doses at 10 to 20 times the prescribed amount, simply by making mistakes while drawing medication from a vial. In 2024, 95% of adverse events<\/a> associated with GLP-1s were related to either how the product was dosed or how it was administered, rather than issues with the drug.<\/p>\n

In addition, some compounded GLP-1s come in different concentrations than the standard forms; five units of one may contain twice as much drug as the other. And the labels aren\u2019t always accurate: compounded GLP-1s may contain more or less of the drug than they claim.\u00a0<\/p>\n

\u201cFor a lot of these forms, you have to dive into truly how much of the drug is in this bottle,\u201d Blyumin said. \u201cEven to clinicians, when we look at it, it\u2019s not always clear.\u201d<\/p>\n

Peptide stability and degradation<\/p>\n

GLP-1 drugs belong to a class of molecules called peptides, which means they are short chains of amino acids \u2014 the building blocks of proteins. Peptides are inherently fragile, prone to falling apart when exposed to heat, light or improper handling.<\/p>\n

FDA-approved versions of the drugs are manufactured and packaged under tightly controlled conditions designed to preserve that stability through shipping and storage. Compounded versions, made in smaller batches without the same manufacturing oversight, are more vulnerable to breaking down before they get to your door. Degraded peptide may lead to a less potent drug without any visible sign of the problem.<\/p>\n

What are the side effects of unapproved GLP-1s?<\/p>\n

The downsides of GLP-1s can be summed up in one message: You don\u2019t know what you\u2019re getting. In many cases, this might mean you\u2019re getting less of the drugs, or less effective drugs, than you think you\u2019re paying for. A lower dose than expected is unlikely to have side effects.<\/p>\n

But an excess dose or extra ingredients may mean that you end up with side effects and symptoms beyond those already associated with GLP-1s, including nausea, vomiting, constipation, diarrhea and headaches are all common.\u00a0<\/p>\n

\u201cIt is difficult to distinguish symptoms from FDA-approved and compounded products,\u201d Basina noted. \u201cEspecially because side effect severity can vary from person to person.\u201d<\/p>\n

But Basina said there are red flags to watch out for if you\u2019re taking a compounded drug:\u00a0<\/p>\n

Signs of severe dehydration such as fainting and confusion or not urinating for eight hours.
\n Pancreatitis, which usually feels like sharp pain in your upper abdomen and back.
\n Gastrointestinal symptoms that don\u2019t improve when you eat smaller meals or take anti-nausea medications.
\n Gastrointestinal symptoms that grow worse rather than easing up the longer you\u2019re on the drug.<\/p>\n

\"Michael<\/p>\n

\n Michael Blyumin and Marina Basina\n <\/p>\n

The 2026 FDA crackdown: What changed?<\/p>\n

Regulatory agencies have been tightening their oversight of compounded GLP-1s for more than a year. Tirzepatide came off the FDA\u2019s official drug shortage list in December 2024, and semaglutide followed in February 2025, eliminating the legal pathway that allowed compounding pharmacies to produce copies of the drugs.<\/p>\n

On April 30, 2026<\/a>, the FDA took the more sweeping step of proposing to permanently exclude semaglutide, tirzepatide and liraglutide from the \u201c503B Bulks List\u201d \u2014 the list of ingredients that large-scale compounding facilities are legally permitted to use. If that change is finalized, which could take several months, it would close the last legal pathway for most compounded GLP-1s.<\/p>\n

At the same time, the FDA sent warning letters<\/a> to dozens of specific companies for making false or misleading claims about their compounded GLP-1 drugs.<\/p>\n

Will you lose access to your compounded GLP-1?<\/p>\n

Not immediately. In June, the FDA extended the public comment period<\/a> for the 503B Bulks List proposal to the end of July.<\/p>\n

Even if finalized as proposed, the rule would apply specifically to 503B outsourcing facilities, the large-scale operations that supply much of the compounded GLP-1 market. Smaller 503A pharmacies, which compound drugs for individual patients based on a prescription, would still be legally permitted<\/a> to make patient-specific versions. However, these pharmacies are more limited in scale and can make GLP-1s for only a narrow set of reasons, not routine prescriptions.<\/p>\n

This proposal doesn\u2019t change access for patients using an FDA-approved GLP-1 \u2014 Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda or Victoza.<\/p>\n

\"\"\/<\/p>\n

Healthy habits for your 60s, 70s & beyond<\/p>\n

\"\"\/<\/p>\n

Healthy habits for your 20s & 30s<\/p>\n

\"Ultraprocessed<\/p>\n

Healthy habits for your 40s & 50s<\/p>\n

\n Previous Next\n <\/p>\n

8
\n 9
\n 2<\/p>\n

What should you do if you\u2019re taking an unapproved GLP-1?<\/p>\n

Basina and Blyumin emphasized that patients shouldn\u2019t panic or stop a medication abruptly \u2014 particularly if it\u2019s used to manage diabetes. Instead, they should explore low-cost FDA-approved options and consult with a clinician about switching.<\/p>\n

\u201cI think people just assume they can\u2019t afford these medications, but there are options they may not know about,\u201d Blyumin said.<\/p>\n

He pointed toward Medicare out-of-pocket caps for some patients and cost-savings options for people who buy in cash directly from the manufacturers. Basina mentioned that older weight-loss drugs like phentermine-topiramate, available as a generic, offer significant savings.\u00a0<\/p>\n

For patients who want to transition from a compounded product to an FDA-approved one, both clinicians cautioned that the process isn\u2019t always straightforward, as it may not be clear what dose a patient on a compounded product had been taking.<\/p>\n

\u201cStart with a lower dose than patient\u2019s reported compounded drug dose and titrate up slowly,\u201d Basina said.<\/p>\n

How to spot unsafe online GLP-1 providers<\/p>\n

If a compounded product is the only option, Basina advised confirming that it comes from a 503B-registered outsourcing facility, rather than an unregistered online seller, and staying under close medical supervision while using it. The FDA\u2019s BeSafeRx program<\/a> can help you locate a licensed online pharmacy in your state.<\/p>\n

Other clues that your compounded prescription may not be legitimate:<\/p>\n

It does not require a prescription.
\n The pharmacy is not located within the U.S.
\n The medication arrives in packaging that is damaged, open, labeled in a foreign language or has no expiration date.
\n Unusual delivery methods. Delivery methods other than injections and oral pills, such as sublingual drops and dissolving tablets, have not been tested in clinical trials.
\n Vague or proprietary ingredient lists. Products marketed as \u201cpersonalized\u201d blends with added vitamins or other ingredients, without a clear clinical rationale, are often designed to tout those additions to sidestep regulations rather than to benefit the patient.<\/p>\n

<\/p>\n

\"\"\/<\/p>\n

Sharing the informed perspectives of those leading medical research, patient care and education at Stanford Medicine<\/p>\n

\"\"\/<\/p>\n

\"\"\/<\/p>\n

Seed oils: What should you know<\/p>\n

\"\"\/<\/p>\n

Young people and nicotine: 5 things to know<\/p>\n

\"Ultraprocessed<\/p>\n

\"\"\/<\/p>\n

Kids, teens and antidepressants<\/p>\n

\"\"\/<\/p>\n

The science behind sunscreen<\/p>\n

\"\"\/<\/p>\n

Understanding the gut-brain connection<\/p>\n

\n Previous Next\n <\/p>\n

Insights
\n 8
\n 9
\n 6
\n 2
\n 3
\n 4
\n 5<\/p>\n","protected":false},"excerpt":{"rendered":"So, are these copycat versions of the weight loss drugs safe? Poison control centers across the U.S. have…\n","protected":false},"author":2,"featured_media":706969,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42],"tags":[19575,847,26672,5573,5237,916,102,61882,234487,6591,6636,59820,31568,22629,202868,123204,56,54,55,7268],"class_list":["post-706968","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-addiction","tag-cancer","tag-cardiology","tag-diabetes","tag-drug-development","tag-genetics","tag-health","tag-health-equity","tag-kidney-health-nephrology","tag-medication","tag-nutrition","tag-precision-health","tag-preventive-medicine","tag-primary-care","tag-psychiatry-mental-health","tag-stanford-medicine","tag-uk","tag-united-kingdom","tag-unitedkingdom","tag-wellness"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/706968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/comments?post=706968"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/706968\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media\/706969"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media?parent=706968"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/categories?post=706968"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/tags?post=706968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}